Similar articles

• Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.

  Pouillart P. Pouillart P. Cancer Treat Rev. 2004 Nov;30(7):643-50. doi: 10.1016/j.ctrv.2004.06.002. Cancer Treat Rev. 2004. PMID: 15531396 Review.
• Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.

  van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. van Dalen EC, et al. Eur J Cancer. 2006 Dec;42(18):3191-8. doi: 10.1016/j.ejca.2006.08.005. Epub 2006 Sep 20. Eur J Cancer. 2006. PMID: 16987655
• Anthracycline cardiotoxicity: one size does not fit all!

  Hershman DL, Neugut AI. Hershman DL, et al. J Natl Cancer Inst. 2008 Aug 6;100(15):1046-7. doi: 10.1093/jnci/djn241. Epub 2008 Jul 29. J Natl Cancer Inst. 2008. PMID: 18664649 No abstract available.
• New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.

  Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. Ryberg M, et al. J Natl Cancer Inst. 2008 Aug 6;100(15):1058-67. doi: 10.1093/jnci/djn206. Epub 2008 Jul 29. J Natl Cancer Inst. 2008. PMID: 18664656
• [Cardiotoxicity of anthracycline].

  Wojtukiewicz MZ, Omyła J, Kozłowski L, Szynaka B. Wojtukiewicz MZ, et al. Postepy Hig Med Dosw. 2000;54(4):467-85. Postepy Hig Med Dosw. 2000. PMID: 11016267 Review. Polish.